Vir Biotechnology, Inc. (VIR) 8-K Current Report: February 26, 2026
Filed: February 26, 2026
Health Care
Biological Products, (No Diagnostic Substances)Vir Biotechnology, Inc. (VIR) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
Vir Biotechnology, Inc. 8-K Feb 26, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Vir Bio priced public offering of 17,647,059 shares at $8.50/share, closing Feb 27, 2026
- • Net proceeds ~$141.1M base; up to ~$162.3M if underwriters exercise full 2,647,058-share overallotment option
- • Dilution risk: total potential new shares ~20.3M if greenshoe exercised fully
- • Bookrunners: Goldman Sachs, Leerink Partners, Evercore, Barclays — broad syndicate signals institutional demand sought
Other Vir Biotechnology, Inc. 8-K Filings
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.